Altace Diabetes Complications Claim May Be Discussed By Cmte.
Executive Summary
King Pharmaceuticals' proposed claim that Altace reduces complications in diabetes patients receiving the drug to decrease cardiovascular events is likely to be a point of discussion at FDA's Cardio-Renal Drugs Advisory Committee on May 1.
You may also be interested in...
King To Submit Additional Studies On Altace Efficacy In Diabetic Patients
King Pharmaceuticals plans to submit additional data from two studies in support of an Altace effect on diabetes complications.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011